Clinical Trial Update: TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating a single TAXUS paclitaxel-eluting stent for de novo coronary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Paclitaxel-Eluting Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 2, Phase 3 | Status: COMPLETED